4922 Federal Register / Vol. 71, No. 19 / Monday, January 30, 2006 / Notices 

Dated: January 20, 2006. 

Jason Brodsky, 

Acting Associate Commissioner for External 

Relations. 

[FR Doc. E6–1069 Filed 1–27–06; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Blood Products Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). At least one portion of the 

meeting will be closed to the public. 

Name of Committee: Blood Products 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on March 9, 2006, from 8 a.m. to 

5 p.m. and March 10, 2006, from 8:30 

a.m. to 4:30 p.m. 

Location: Hilton Hotel Washington 

DC North/ Gaithersburg, 620 Perry 

Pkwy., Gaithersburg, MD 20877. 

Contact Person: Donald W. Jehn, or 

Pearline K. Muckelvene, Center for 

Biologics Evaluation and Research 

(HFM–71), Food and Drug 

Administration, 1401 Rockville Pike, 

Rockville, MD 20852, 301–827–0314, or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

3014519516. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: On March 9, 2006, in the 

morning the committee will hear 

updates on the following topics: (1) 

Summary of the Department of Health 

and Human Services Advisory 

Committee on Blood Safety and 

Availability January 2006 meeting; (2) 

current considerations for blood donor 

screening for West Nile Virus; (3) 

classification of transfusion recipient 

identification (ID) systems; and (4) 

summary of the workshop on behaviorbased donor deferrals in the Nucleic 

Acid Test (NAT) era. The committee 

will then discuss rapid tests for 

detection of bacterial contamination of 

platelets. In the afternoon, the 

committee will discuss public 

comments on the ‘‘Guidance for 

Industry and FDA Review Staff: 

Collection of Platelets by Automated 

Methods (DRAFT).’’ On March 10, 2006, 

in the morning the committee will 

discuss proposed studies to support the 

approval of over-the-counter (OTC) 

home-use human immunodeficiency 

virus (HIV) test kits. In the afternoon, 

the committee will hear an overview of 

the research programs of the Office of 

Blood Research and Review, Center for 

Biologics Evaluation and Research 

(CBER), as presented to a subcommittee 

of the Blood Products Advisory 

Committee during their site visit on July 

22, 2005, and discuss a subcommittee 

report in closed session. Additionally, 

the committee will hear an overview of 

the research programs in the Laboratory 

of Biochemistry and Vascular Biology 

and the Laboratory of Cellular 

Hematology, Division of Hematology, 

Office of Blood Research and Review, 

CBER and in closed session discuss the 

report from the laboratory site visit of 

October 6, 2005. 

Procedure: On March 9, 2006, the 

meeting is open to the public. On March 

10, 2006, from 8:30 a.m. to 3:15 p.m. 

and again from 4:15 p.m. to 4:30 p.m., 

the meeting is open to the public. 

Interested persons may present data, 

information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person by February 

28, 2006. Oral presentations from the 

public will be scheduled on March 9, 

2006, between approximately 9:45 a.m. 

to 11:30 a.m. and 2:30 p.m. to 3:30 p.m. 

On March 10, 2006, oral presentations 

from the public will be scheduled 

between approximately 9:30 a.m. to 

10:30 a.m. and 2:45 p.m. to 2:55 p.m. 

Time allotted for each presentation may 

be limited. Those desiring to make 

formal oral presentations should notify 

the contact person before February 28, 

2006, and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation. 

Closed Committee Deliberations: On 

March 10, 2006, from 3:15 p.m. to 4:15 

p.m., the meeting will be closed to 

permit discussion where disclosure 

would constitute a clearly unwarranted 

invasion of personal privacy (5 U.S.C. 

552b(c)(6)) and to permit discussion and 

review of trade secret and/or 

confidential information (5 U.S.C. 

552b(c)(4)). The committee will discuss 

a subcommittee’s report of the internal 

research programs in the Office of Blood 

Research and Review, CBER. In 

addition, the committee will discuss the 

site visit report for the Laboratory of 

Biochemistry and Vascular Biology and 

Laboratory of Cellular Hematology, 

Division of Hematology, Office of Blood 

Research and Review, CBER. 

Following this closed session, the 

committee will provide summarized 

comments regarding the Office Site Visit 

Report in an open public session. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Donald W. 

Jehn or Pearline K. Muckelvene at least 

7 days in advance of the meeting. Notice 

of this meeting is given under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: January 20, 2006. 

Jason Brodsky, 

Acting Associate Commissioner for External 

Relations. 

[FR Doc. E6–1075 Filed 1–27–06; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; Comment 

Request Evaluation of the Impact of 

the New Conflicts of Interest 

Regulations on the National Institutes 

of Health’s Ability To Recruit and 

Retain Staff 

Summary: In compliance with the 

requirement of Section 3506(c)(2)(A) of 

the Paperwork Reduction Act of 1995, 

for opportunity for public comment on 

proposed data collection projects, the 

Office of Human Resources (OHR) of the 

National Institutes of Health (NIH) will 

publish periodic summaries of proposed 

projects to be submitted to the office of 

Management and Budget (OMB) for 

review and approval. 

Proposed Collection 

Title: Evaluation of the Impact of the 

Conflicts of Interest Regulations on the 

National Institutes of Health’s Ability to 

Recruit and Retain Staff. Type of 

Information Collection Request: New 

Collection. Need and Use of Information 

Collection: To assess the impact of new 

Department of Health and Human 

Services (HHS) ethics regulations on the 

NIH’s ability to continue to attract and 

recruit highly qualified scientific 

personnel. This information collection 


cprice-sewell on PROD1PC66 with NOTICES
Federal Register / Vol. 71, No. 19 / Monday, January 30, 2006 / Notices 4923 

is essential to the mission of the NIH [42 

U.S.C. 241 and 282(b)(1)]. In December 

2003, the House Energy and Commerce 

Committee raised concerns about 

potential conflicts of interest at NIH. In 

response to these concerns, the NIH 

Director, Dr. Elias Zerhouni, ordered an 

internal investigation into consulting 

agreements at NIH and in June 2004 

proposed changes to the agency’s 

conflict-of-interest policies. Effective 

February 3, 2005, the new regulations (5 

CFR Parts 5501 and 5502, 

‘‘Supplemental Standards of Ethical 

Conduct and Financial Disclosure 

Requirements for Employees of the 

Department of Health and Human 

Services,’’ FR Vol. 70, No. 22, Thursday, 

February 3, 2005, 5543–5565, and Vol. 

70, No. 168, Wednesday, August 31, 

2005, 51559–51574) apply to all NIH 

employees and, among other things, 

place limits on certain financial 

holdings of the most senior NIH 

employees, their spouses, and minor 

children and on certain outside 

activities in which NIH staff may 

engage. Gauging both the immediate and 

longer term impact of these new rules is 

crucial to NIH’s ability to develop and 

maintain a world-class staff. This 

project will produce data that will help 

NIH and HHS leaders determine the 

impact of the regulations and how to 

minimize the effect of the regulations on 

NIH’s ability to recruit and retain staff. 

NIH intends to survey potential 

applicants for NIH employment from 

scientific organizations from which NIH 

has traditionally drawn leading 

scientific personnel, and those senior 

scientists and administrators who have 

voluntarily left NIH since February 

2005. This will allow NIH to determine 

whether the regulations impact 

individuals’ attitudes about 

employment at NIH and the likelihood 

of their joining and/or leaving the 

agency. 

Frequency of Response: One time. 

Affected Public: Individuals and 

households. Type of Respondent: Highly 

trained and qualified scientists engaged 

in medicine and life sciences research. 

The annual reporting burden is as 

follows: Estimated Number of 

Respondents: 500; Estimated Number of 

Responses per Respondent: One; 

Average Burden Hours Per Response: 15 

minutes; and Estimated Total Annual 

Burden Hours Requested: 117 hours. 

The annualized cost to respondents is 

estimated at $3,850. There are no 

Capital Costs, Operating Costs, or 

Maintenance Costs to report. 

Request for Comments 

Written comments and/or suggestions 

from the public and affected agencies 

should address one or more of the 

following points: (1) Evaluate whether 

the proposed collection of information 

is necessary for the proper performance 

of the function of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) (enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Minimize the burden 

of the collection of information on those 

who are to respond, including the use 

of appropriate automated electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Comments Due Date 

Comments regarding this information 

collection are best assured of having 

their full effect if received within 60 

days of the date of this publication. 

For More Information or to Direct 

Comments: To submit comments, to 

request more information on the 

proposed project, or to obtain a copy of 

the data collection plans and 

instruments, contact Mr. Richard M. 

Taffet, Acting Director, Client Services 

Division; Office of Human Resources, 

Office of the Director, National 

Institutes of Health, Room 2–D234, East 

Jefferson Street, Bethesda, MD 20892–

8502, or call the non-toll-free number 

(301) 402–6627, or e-mail your 

comments or request, including your 

address, to: taffetr@mail.nih.gov. 

Dated: January 23, 2006. 

Raynard S. Kington, 

Deputy Director, National Institutes of Health. 

[FR Doc. 06–845 Filed 1–27–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SBIR Topic 

208 (Phase I) ‘‘Targetry Systems for 

Production of Research Radionucleides’’. 

Date: February 23, 2006. 

Time: 12 p.m. to 4 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: C. Michael Kerwin, PhD, 

MPH, Scientific Review Administrator, 

Special Review and Logistics Branch, 

Division of Extramural Activities, National 

Cancer Institute, National Institutes of 

Health, 6116 Executive Boulevard, Room 

8057, MSC 8329, Bethesda, MD 20892–8329, 

301–496–7421, kerwinm@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: January 23, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–846 Filed 1–27–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SBIR Topic 

207 (Phase I) ‘‘Synthesis Modules for 

Radiopharmaceutical Production’’. 


cprice-sewell on PROD1PC66 with NOTICES